Error message

  • Notice: Undefined index: custom_date_format in date_formatter_format() (line 447 of /data/crossleylab.unsw.edu.au/www/sites/all/modules/contrib/date/date.module).
  • Notice: Undefined index: formatted_timezone in theme_date_display_combination() (line 139 of /data/crossleylab.unsw.edu.au/www/sites/all/modules/contrib/date/date.theme).
  • Notice: Undefined index: formatted_time in theme_date_display_combination() (line 145 of /data/crossleylab.unsw.edu.au/www/sites/all/modules/contrib/date/date.theme).
  • Notice: Undefined index: formatted_time in theme_date_display_combination() (line 147 of /data/crossleylab.unsw.edu.au/www/sites/all/modules/contrib/date/date.theme).
A natural regulatory mutation in the proximal promoter elevates fetal globin expression by creating a de novo GATA1 site
Author: 

Martyn, G. E., Wienert, B., Kurita, R., Nakamura, Y., Quinlan, K. G., & Crossley, M.

Key Summary: 

β-hemoglobinopathies, such as sickle cell disease and β-thalassemia result from mutations in the adult β-globin gene. Reactivating the developmentally silenced fetal γ-globin gene elevates fetal hemoglobin levels and ameliorates symptoms of β-hemoglobinopathies. The continued expression of fetal γ-globin into adulthood occurs naturally in a genetic condition termed Hereditary Persistence of Fetal Hemoglobin (HPFH). Point mutations in the fetal γ-globin proximal promoter can cause HPFH. The -113A>G HPFH mutation falls within the -115 cluster of HPFH mutations, a binding site for the fetal globin repressor BCL11A. We demonstrate that the -113A>G HPFH mutation, unlike other mutations in the cluster, does not disrupt BCL11A binding but rather creates a de novo binding site for the transcriptional activator GATA1. Introduction of the -113A>G HPFH mutation into erythroid cells using the clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) system increases GATA1 binding and elevates fetal globin levels. These results reveal the mechanism by which the -113A>G HPFH mutation elevates fetal globin and demonstrate the sensitivity of the fetal globin promoter to point mutations that often disrupt repressor binding sites but here create a de novo site for an erythroid activator.